The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 7, Issue 9, Pages 1137-1147
Publisher
Future Science, LTD
Online
2015-07-01
DOI
10.4155/fmc.15.55
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis
- (2015) FoSheng Hsu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- mTOR Links Environmental Signals to T Cell Fate Decisions
- (2015) Nicole M. Chapman et al. Frontiers in Immunology
- Therapeutic targets for rheumatoid arthritis: Progress and promises
- (2014) Abdullah Alghasham et al. AUTOIMMUNITY
- Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy
- (2014) B. D. Hopkins et al. CLINICAL CANCER RESEARCH
- Where is mTOR and what is it doing there?
- (2014) Charles Betz et al. JOURNAL OF CELL BIOLOGY
- Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
- (2014) D. Cirstea et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
- (2014) Guillaume Canaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN function: the long and the short of it
- (2014) Benjamin D. Hopkins et al. TRENDS IN BIOCHEMICAL SCIENCES
- Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation
- (2013) Shigenori Nagai et al. Annals of the New York Academy of Sciences
- Phosphatidylinositol 3,5-bisphosphate: Low abundance, high significance
- (2013) Amber J. McCartney et al. BIOESSAYS
- Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
- (2013) Thomas W. Grunt et al. CURRENT CANCER DRUG TARGETS
- Enhancement of PLGF production by 15-(S)-HETE via PI3K-Akt, NF-κB and COX-2 pathways in rheumatoid arthritis synovial fibroblast
- (2013) Ming-Yueh Wu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment
- (2013) Xiaoqing Lv et al. Expert Opinion on Drug Discovery
- Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells
- (2013) Yutaka Kurebayashi et al. GENES TO CELLS
- Targeting Interleukin-22 in Psoriasis
- (2013) Ji-Qing Hao INFLAMMATION
- IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro
- (2013) Shoichi Kaneshiro et al. JOURNAL OF BONE AND MINERAL METABOLISM
- mTOR signaling cascade in psoriatic disease: Double kinase mtor inhibitor a novel therapeutic target
- (2013) SibaR Raychaudhuri et al. INDIAN JOURNAL OF DERMATOLOGY
- PI3 Kinase δ Is a Key Regulator of Synoviocyte Function in Rheumatoid Arthritis
- (2012) Beatrix Bartok et al. AMERICAN JOURNAL OF PATHOLOGY
- Updates of mTOR Inhibitors
- (2012) Hongyu Zhou et al. Anti-Cancer Agents in Medicinal Chemistry
- The role of S6K1 in ER-positive breast cancer
- (2012) Marina K. Holz CELL CYCLE
- New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
- (2012) Bradley A. Wisler et al. Current Signal Transduction Therapy
- IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade
- (2012) Anupam Mitra et al. CYTOKINE
- Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2
- (2012) K. D. Copps et al. DIABETOLOGIA
- Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats
- (2012) Kazuhiko Haruta et al. INFLAMMATION RESEARCH
- Enhancement of placenta growth factor expression by oncostatin M in human rheumatoid arthritis synovial fibroblasts
- (2012) Huang-Ju Tu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors
- (2012) Felix Gonzalez-Lopez de Turiso et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel PI3-Kinase δ Specific Inhibitors for the Treatment of Rheumatoid Arthritis: Taming CYP3A4 Time-Dependent Inhibition
- (2012) Brian S. Safina et al. JOURNAL OF MEDICINAL CHEMISTRY
- Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
- (2012) Jeremy M. Murray et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.
- (2012) A. Naing et al. MOLECULAR CANCER THERAPEUTICS
- Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
- (2012) E. Choy RHEUMATOLOGY
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies
- (2012) Kamal D. Puri et al. Frontiers in Immunology
- Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis
- (2011) Torsten Lowin et al. ARTHRITIS AND RHEUMATISM
- Targeting mTOR globally in cancer: Thinking beyond rapamycin
- (2011) Boris Shor et al. CELL CYCLE
- ATP-Competitive Inhibitors of mTOR: An Update
- (2011) S. Schenone et al. CURRENT MEDICINAL CHEMISTRY
- Selective PI3Kδ inhibitors, a review of the patent literature
- (2011) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review
- (2011) Arie Zask et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
- (2011) J. Baselga ONCOLOGIST
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
- (2010) Sébastien Albert et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation
- (2010) Sandra Beer-Hammer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The Discovery of Novel Experimental Therapies for Inflammatory Arthritis
- (2010) Charles J. Malemud MEDIATORS OF INFLAMMATION
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin
- (2010) Kostas Stylianou et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- B Cell Receptor Signaling: Picky About PI3Ks
- (2010) J. J. Limon et al. Science Signaling
- The PI3K Isoforms p110 and p110 Are Essential for Pre-B Cell Receptor Signaling and B Cell Development
- (2010) F. Ramadani et al. Science Signaling
- The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity
- (2009) M. D. Säemann et al. AMERICAN JOURNAL OF TRANSPLANTATION
- A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1
- (2009) Jingxiang Huang et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
- (2009) Charles Malemud et al. Current Signal Transduction Therapy
- Targeting the mTOR Signaling Network for Cancer Therapy
- (2009) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- The multiple facets of mTOR in immunity
- (2009) Thomas Weichhart et al. TRENDS IN IMMUNOLOGY
- The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
- (2008) T Weichhart et al. ANNALS OF THE RHEUMATIC DISEASES
- B-lineage commitment prior to surface expression of B220 and CD19 on hematopoietic progenitor cells
- (2008) R. Mansson et al. BLOOD
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started